Maximum quantity allowed is 999
Please select the quantity
CAS RN: 10238-21-8 | Product Number: G0382
Glibenclamide
×
![]()
×
Purity: >98.5%(T)(HPLC)
Synonyms:
- 5-Chloro-N-[4-(3-cyclohexylureidosulfonyl)phenethyl]-2-methoxybenzamide
- Glyburide
Product Documents:
| Size | Unit Price | Hyderabad | Japan* | Quantity |
|---|---|---|---|---|
| 5G |
₹2,600.00
|
6 | ≥40 |
|
| 25G |
₹6,700.00
|
5 | ≥40 |
|
*Upon orders receipt, Hyderabad stocks will be dispatched on the same day.
*Items available in Japan warehouse will be dispatched in 10-12 working days.
*INR price is exclusive of domestic taxes applicable.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
| Product Number | G0382 |
Purity / Analysis Method 
|
>98.5%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__2__3H__2__8ClN__3O__5S = 494.00 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature
|
Refrigerated (0-10°C) |
| Condition to Avoid | Heat Sensitive |
| CAS RN | 10238-21-8 |
| Reaxys Registry Number | 2230085 |
| PubChem Substance ID | 135726994 |
| Merck Index (14) | 4478 |
| MDL Number | MFCD00056625 |
Specifications
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.5 area% |
| Purity(Neutralization titration) | min. 98.5 % |
| Melting point | 172.0 to 176.0 °C |
Properties (reference)
| Melting Point | 174 °C |
| Solubility in water | Insoluble |
| Solubility (soluble in) | Dimethylformamide |
| Solubility (slightly sol. in) | Ethanol, Methanol |
GHS
Related Laws:
| RTECS# | YS4725200 |
Transport Information:
Application
Glibenclamide: A Sulfonylurea ATP-Dependent K+ Channel Antagonist
Glibenclamide belongs to sulfonylurea antidiabetics which increase the release of insulin from pancreatic B-cells. Sulfonylurea antidiabetics inhibit ATP-gated K+ channels and thereby cause depolarization of the B-cell membrane. The depolarization leads to activation of voltage-dependent Ca channels and Ca2+ influx into the B-cell, and eventually increases insulin release. Recently, a combination agent with metformin [M2009] is also used for the treatment of Type 2 diabetes. (The product is for research purpose only.)
References
- Glyburide: a second-generation sulfonylurea hypoglycemic agent. History, chemistry, metabolism, pharmacokinetics, clinical use and adverse effects (a review)
- Sulfonylurea receptor 2B and Kir6.1 form a sulfonylurea-sensitive but ATP-insensitive K+ channel
- Cooperative binding of ATP and MgADP in the sulfonylurea receptor is modulated by glibenclamide
- Sulfonylurea stimulation of insulin secretion (a review)
- Glyburide/metformin tablets: a new therapeutic option for the management of Type 2 diabetes (a review)
- The development and validation of liquid chromatography method for the simultaneous determination of metformin and glipizide, gliclazide, glibenclamide, or glimperide in plasma
- Simultaneous estimation of six anti-diabetic drugs-glibenclamide, gliclazide, glipizide, pioglitazone, repaglinide and rosiglitazone: development of a novel HPLC method for use in the analysis of pharmaceutical formulations and its application to human plasma assay
- Liquid chromatography tandem mass spectrometry method for simultaneous determination of antidiabetic drugs metformin and glyburide in human plasma
PubMed Literature
Documents
Product Articles
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.